31st Oct 2025 02:46
(Alliance News) - Daiichi Sankyo Co Ltd and AstraZeneca PLC on Friday said they began new phase 3 clinical trial testing of an intravenous treatment for advanced lung cancer.
The Tokyo-based pharmaceutical company said they started the Destiny-Lung06 clinical trial that will compare Enhertu with pembrolizumab against a standard treatment that includes chemotherapy and immunotherapy.
The trial focuses on patients with a type of advanced lung cancer that has too much of a growth related protein called human epidermal growth factor receptor two and low levels of another marker called Programmed Death-Ligand one.
According to Daiichi, these patients don’t have many treatment options.
"In the trial, we are evaluating whether replacing traditional chemotherapy with Enhertu and combining it with standard of care immunotherapy could potentially improve outcomes for patients in the first-line metastatic setting," said Abderrahmane Laadem, head of Late-Stage Oncology Clinical Development at Daiichi Sankyo.
Enhertu was developed by Daiichi Sankyo and is jointly commercialised with AstraZeneca.
Shares in Daiichi Sankyo were up 1.6% at JPY3,904.00 in Tokyo on Friday afternoon, while AstraZeneca shares closed down 0.3% at 12,522.00 pence in London on Thursday.
By Judy Amaca, Alliance News reporter Asia-Pacific
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Astrazeneca